olympex solutions ghk-cu — Technical Lot Record · Lyos Labs GHK-Cu 50MG - Oneday Compounds

Uses: In combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic nonsquamous NSCLC, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma receptor tyrosine kinase (ALK) genomic tumor aberrations In combination with cisplatin, for the initial treatment of patients with locally advanced or metastatic, nonsquamous NSCLC As a single agent, for the maintenance treatment of patients with locally advanced or metastatic nonsquamous NSCLC whose disease has not progressed after 4 cycles of platinum-based first-line chemotherapy As a single agent, for the treatment of patients with recurrent, metastatic nonsquamous NSCLC after prior chemotherapy Usual Adult Dose for Malignant Pleural Mesothelioma 500 mg/m2 IV on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity Use: In combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery Renal Dose Adjustments CrCl 45 mL/min or greater: No adjustment recommended CrCl less than 45 mL/min: Not recommended If renal toxicity develops during therapy: This drug should be withheld until CrCl is 45 mL/min or greater

There is no evidence from long-term use in patients with pernicious anemia that cyanocobalamin is carcinogenic

Please note, this appointment does not cover our Weight Management or Hormone Replacement Therapy programs

Comprehensive Consultation We review your symptoms, goals, lifestyle, and medical history in detail